Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Altheos logo — Pioneering novel treatments with promising small molecule dr...

Altheos

Pioneering novel treatments with promising small molecule drugs for glaucoma, supported by significant Series A funding.

Founded 2010 Series A Total: $32.50M Biotechnology, Health Care

General Information

Company Name Altheos
Founded Year 2010
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Altheos. To contact Altheos, visit altheos.net.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Altheos compare?

A PDF of Altheos and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Altheos soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Altheos

Altheos is an early-stage biopharmaceutical company based in the San Francisco Bay area, focusing on the development of innovative small molecule drugs for the treatment of glaucoma. The company gained significant traction in March 2010, securing $20 million in Series A financing led by Bay City Capital and supported by Novo A/S, Canaan Partners, Life Science Angels, and Atheneos Capital. This substantial investment is earmarked for the advancement of ATS907, a selective Rho-kinase inhibitor intended for the topical treatment of glaucoma. Notably, Altheos licensed this promising compound from a Japanese pharmaceutical company and has a broad portfolio of highly effective compounds designed specifically for glaucoma treatment. Overall, Altheos seems to have garnered significant support from key players in the industry, and its focus on pioneering novel treatments for glaucoma positions it well for success in the healthcare and biotechnology sectors. The $12.50 million Series A investment further indicates continued confidence in the company's potential, with Novo Holdings, Canaan Partners, and Bay City Capital demonstrating their ongoing commitment to Altheos' development. This strategic support, combined with the promising pipeline of small molecule drugs, positions Altheos as a compelling player in the quest for innovative glaucoma treatments.

Business keywords: Biopharmaceutical, Small molecule drugs, Glaucoma treatment, Rho-kinase inhibitor, Series A funding, San Francisco Bay area, Clinical stage, Drug development, Japanese pharmaceutical, Licensing agreement

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $12.50M 3
Novo Holdings Canaan Partners Bay City Capital
Novo Holdings, Canaan Partners +1
09 Feb 2012
Series A $20.00M 5
Novo Holdings Canaan Partners Life Science Angels
Novo Holdings, Canaan Partners +3
05 Apr 2010

Altheos Alternatives & Competitors

View All Alternatives
Altheos vs
Ambit
Ambit

Driving breakthroughs in cancer and inflammatory disease treatment through pioneering kinase inhibit...

Venture round
197 employees
Biopharma, Biotechnology
Altheos vs
Adastra Pharmaceuticals
Adastra Pharmaceuticals United States

Adastra is committed to transforming cancer care.

Venture round
11-50 employees
Biotechnology, Health Care
Altheos vs
Tetralogic Pharmaceuticals
Tetralogic Pharmaceuticals

TetraLogic Pharmaceuticals (Nasdaq: TLOG) is a clinical-stage biopharmaceutical company focused on d...

Convertible Note
10 employees
Biotechnology, Health Care
View all alternatives

FAQ About Altheos

Pioneering novel treatments with promising small molecule drugs for glaucoma, supported by significant Series A funding.
Altheos was founded in 2010.
Altheos operates in Biotechnology and Health Care. Its work centres on Biopharmaceutical, Small molecule drugs, Glaucoma treatment and Rho-kinase inhibitor.
Altheos has completed 2 funding rounds, raising a total of $32.50M. The latest funding stage is Series A.
Top alternatives and competitors to Altheos include Ambit, Adastra Pharmaceuticals, Tetralogic Pharmaceuticals, Treadwell Therapeutics, Inc., Advenchen Laboratories, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Altheos and Ambit are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Altheos, https://bouncewatch.com/company/altheos, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes